ID   KMCH-1
AC   CVCL_7970
SY   KMCH1; KMCH
DR   BTO; BTO:0003310
DR   cancercelllines; CVCL_7970
DR   Cell_Model_Passport; SIDM01800
DR   DepMap; ACH-001853
DR   Wikidata; Q54900108
RX   CelloPub=CLPUB00275;
RX   PubMed=3032760;
RX   PubMed=7537711;
RX   PubMed=9023415;
RX   PubMed=9178645;
RX   PubMed=10347112;
RX   PubMed=32899426;
RX   PubMed=35640676;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~39 hours (PubMed=3032760).
CC   HLA typing: A*11:01,31:01; B*51:01; C*14:02; DRB1*08:02 (PubMed=9178645).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr346Cys (c.1037A>G); ClinVar=VCV000480380; Zygosity=Unspecified (DepMap=ACH-001853).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): DepMap=ACH-001853
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 10
ST   D18S51: 13
ST   D21S11: 29
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   D8S1179: 10,14
ST   FGA: 22
ST   Penta D: 9
ST   Penta E: 11,18
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C3828; Combined hepatocellular carcinoma and cholangiocarcinoma
DI   ORDO; Orphanet_529852; Combined hepatocellular carcinoma and cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 22
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=3032760; DOI=10.1002/hep.1840070322;
RA   Murakami T., Yano H., Maruiwa M., Sugihara S., Kojiro M.;
RT   "Establishment and characterization of a human combined
RT   hepatocholangiocarcinoma cell line and its heterologous
RT   transplantation in nude mice.";
RL   Hepatology 7:551-556(1987).
//
RX   PubMed=7537711; DOI=10.1002/hep.1840210510;
RA   Haramaki M., Yano H., Fukuda K., Momosaki S., Ogasawara S., Kojiro M.;
RT   "Expression of CD44 in human hepatocellular carcinoma cell lines.";
RL   Hepatology 21:1276-1284(1995).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
//
RX   PubMed=10347112; DOI=10.1002/hep.510290624;
RA   Yano H., Iemura A., Haramaki M., Ogasawara S., Takayama A., Akiba J.,
RA   Kojiro M.;
RT   "Interferon alfa receptor expression and growth inhibition by
RT   interferon alfa in human liver cancer cell lines.";
RL   Hepatology 29:1708-1717(1999).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510;
RA   Scherer D., Davila-Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//